Loading…
Reported covered position: Legislative Assistant, Sen. Frank Lautenberg
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Great Basin National Heritage Area and Mormon Pioneer National Heritage Area Extension Act
Client: ORGANON & CO. · Firm: ORGANON & CO.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORGANON & CO. via ORGANON & CO.
2024 · first_quarter · Q1
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, White House Office
ORGANON & CO. via ORGANON & CO.
2023 · fourth_quarter · Q4
Source: Senate LDA
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · third_quarter · Q3
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · second_quarter · Q2
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · first_quarter · Q1
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · fourth_quarter · Q4
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · third_quarter · Q3
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · second_quarter · Q2
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · first_quarter · Q1
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2021 · fourth_quarter · 4A
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORGANON & CO. via ORGANON & CO.
2021 · fourth_quarter · Q4
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORGANON & CO. via ORGANON & CO.
2021 · third_quarter · Q3
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2021 · second_quarter · Q2
Title X funding
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2021 · second_quarter · RR
Access to medicines, Family planning, Biosimilars
Access to medicines, Family planning, Biosimilars
Access to medicines, Family planning, Biosimilars